Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Determination of the effect of Neugranin on the duration and severity of severe neutropenia.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Teva Pharmaceutical Industries
• Treatments: Docetaxel; Doxorubicin; Lenograstim; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• Breast cancer patients scheduled to receive the AT regimen (doxorubicin/ docetaxel).

Exclusion Criteria:

• Subjects may have received no more than 1 prior chemotherapy regimen (including adjuvant therapy if given within the last 12 months).